Biocon Biologics to offer 15% stake to Serum Institute Life Sciences

Under the alliance, BBL will get committed access to 100 million doses of vaccines annually for 15 years and commercialisation rights of the SILS vaccine portfolio for global markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2XokJ7W
via IFTTT